BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

infigratinib: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 1 upcoming FDA event(s), 0 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: QED Therapeutics, a BridgeBio company, BridgeBio Pharma, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
2028-01-01 (half)PDUFA date (company-disclosed)pendingBridgeBio Pharma, Inc. BBIOinfigratinibPDUFA first half of 2028 - BridgeBio Pharma, Inc. (infigratinib)

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01 est.P2/P3QED Therapeutics, a BridgeBio companyNCT06873035 An Interventional Study of Infigratinib in Children With HypochondroplasiaHypochondroplasiaenrolling by invitation24

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
None in the last 180 days.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.